Background {#Sec1}
==========

Chronic constipation is a common condition that may suggest digestive tract lesions, such as colon cancer, or systemic diseases, such as thyroid disease. As the elderly population increases, so does the number of patients with chronic constipation. Chronic constipation greatly impairs a patient's quality of life (QOL), and improving it can address both physical and mental QOL \[[@CR1]\]. The prevalence of chronic constipation in dialysis patients based on evaluations using the Gastrointestinal Symptom Rating Scale was reported to be 36.3--66.7% \[[@CR2]\]. In hemodialysis patients, constipation causes include water restriction, water removal by dialysis, inadequate intake of dietary fiber due to potassium restriction and the associated changes in intestinal microflora, lack of exercise, decreased intestinal tract motility due to aging and muscle weakness, diabetic autonomic nervous system disorder, intake of potassium inhibitors and phosphorus adsorbents, and tolerance due to abuse of irritant laxatives.

Elobixibat, a novel local-acting and highly selective inhibitor of the ileal bile acid transporter that is expressed in the terminal ileum, had been used to treat chronic constipation and was shown to increase bile acid levels in the colon, subsequently enhancing colonic motility and secretion \[[@CR3]--[@CR6]\]. However, there had been no reports on the efficacy of elobixibat in hemodialysis patients with chronic constipation. This aim of this study was to assess the efficacy of elobixibat on the QOL and its effect on the Bristol Stool Form Scale (BSFS) score and the number of spontaneous bowel movements (SBMs) per week of dialysis patients with chronic constipation.

Methods {#Sec2}
=======

Subjects {#Sec3}
--------

We enrolled patients who answered the questionnaire before and after elobixibat intake and who had taken elobixibat in addition to other laxatives to relieve the symptoms of chronic constipation. This retrospective observational study was conducted by collecting data from May 2018 to May 2019. We investigated 27 patients who were on maintenance dialysis three times per week. Three patients underwent dialysis at the Tokyo Women's Medical University and 24 patients did at the Nerima Sakuradai Clinic. All patients satisfied the Rome 3 diagnostic criteria for functional constipation and were treated in accordance with the clinical guidelines of the Japanese Society for Dialysis Therapy \[[@CR7]--[@CR11]\]. Written informed consent was obtained from each study subject. The study's protocol was approved by Tokyo Women's Medical University's ethics committee and was conducted in accordance with the 2000 revised Helsinki Declaration of 1975.

Data collection {#Sec4}
---------------

Age, sex, weight, etiology of end-stage renal disease, dialysis duration, comorbidities, laboratory data, the Japanese version of the Patient Assessment of Constipation-Quality of Life (PAC-QOL) questionnaire \[[@CR12], [@CR13]\], self-reported BSFS score \[[@CR14]\], and the number of SBMs per week were obtained from the patients' medical records. The conventional kinetic measure for urea, known as the Kt/V (single pool), was used to estimate the dialysis dose. The values of thyroid stimulating hormone, free triiodothyronine, free thyroxine, and beta-2 microglobulin were based on the latest blood collection.

Statistical analysis {#Sec5}
--------------------

Data were presented as mean ± standard deviation and as medians and interquartile range. The PAC-QOL score, BSFS score, and the number of SBMs per week before and after 4 weeks of elobixibat intake were compared using the Wilcoxon's rank-sum test. Kendall rank correlation coefficient was used to examine bivariate associations. According to the recommendations the of American Statistical Association on *P* values \[[@CR15], [@CR16]\], we used the SPSS Bayesian methods to confirm the stability and robustness of our results. A value of *p* \< 0.005 was considered statistically significant. All statistical analyses were performed with SPSS version 25.0 (IBM Corp.; Armonk, NY, USA).

Results {#Sec6}
=======

Twenty-seven patients were enrolled in this study. Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"} show the characteristics of enrolled patients. There were 18 men and nine women. The mean age was 70 years, and the mean dialysis duration was 8 years. There were no patients with diseases that caused colonic stenosis, such as colon cancer and Crohn's disease by abdominal echography, abdominal CT, or colonoscopy. There were no patients with biliary atresia and Parkinson's disease. The types of the other laxatives taken were one in 13 patients, two in 10 patients, and three in 4 patients. There were no patients with liver dysfunction. The patients did not show any liver dysfunction, psychoneurotic or circulatory illness, allergy, blood cell abnormalities, or increased Creatine phosphokinase after taking Elobixibat. Table 1The characteristics of enrolled patientsVariableMean ± SD and Median \[IQR\]Number of enrolled patients27Sex (Male/Female)18/9Etiology of end-stage renal diseaseDiabetic nephropathy, 12 patientsNephrosclerosis, 6 patientsCGN, 6 patientsADPKD, 2 patientsGraft loss, 1 patientAge (year)70 ± 13, 75 \[57, 80\]Dialysis duration (year)8 ± 9, 6 \[1,11\]Dry weight (kg)58.1 ± 13.3, 58.1 \[53.7, 61.5\]Single pool Kt/V1.08 ± 0.25, 1.11 \[0.86, 1.30\]Concomitant laxative1 type drug: 13 patients2 types drugs: 10 patients3 types drugs: 4 patientsType of concomitant laxativeSennosides A and B, 26 patientsSodium picosulfate hydrate, 5 patientsGlycerine enema, 1 patientLactulose, 2 patientsSodium dihydrogen phosphate/sodium hydrogen carbonate, 2 patientsLubiprostone, 5 patientsLactomin, 3 patientsDaikenchuto, 1 patientPhosphate binder0 drug, 3 patients1 type of drug, 15 patients2 types of drug, 9 patientsType of phosphate binderLantern carbonate, 6 patientsCalcium carbonate, 19 patientsFerric citrate, 6 patientsSucroferric oxyhydroxide, 2 patients*CGN* chronic glomerulonephritis, *ADPKD* autosomal dominant polycystic kidney disease Table 2The laboratory data of enrolled patientsVariableMean ± SD, median \[IQR\]Hemoglobin (g/dL)10.7 ± 1.2, 10.7 \[9.9, 11.7\]Total protein (g/dL)6.3 ± 0.5, 6.4 \[6.0, 6.6\]Albumin (g/dL)3.4 ± 0.4, 3.4 \[3.2, 3.6\]Blood urea nitrogen (mg/dL)56.0 ± 13.2, 56.4 \[45.1, 68.9\]Creatinine (mg/dL)9.3 ± 3.0, 9.8 \[6.9, 10.8\]Uremic acid (mg/dL)7.1 ± 1.2, 7.3 \[6.3, 7.9\]Aspartate aminotransferase (U/L)14 ± 7, 12 \[10, 14\]Alanine aminotransferase (U/L)10 ± 6, 8 \[7, 13\]Alkaline phosphatase (U/L)251 ± 102, 217 \[179, 291\]Lactate dehydrogenase (U/L)200 ± 55, 191 \[169, 208\]γ-glutamyltransferase (U/L)24 ± 21, 17 \[13, 25\]Total bilirubin (mg/dL)0.3 ± 0.1, 0.2 \[0.2, 0.3\]Cholinesterase (U/L)195 ± 60, 182 \[172, 219\]Creatine phosphokinase (U/L)93 ± 75, 67 \[45, 113\]Iron (μg/dL)54 ± 25, 45 \[35, 76\]Total iron binding capacity (μg/dL)249 ± 46, 248 \[215, 277\]Ferritin (ng/mL)140 ± 148, 82 \[32, 211\]Thyroid stimulating hormone (μU/mL)2.13 ± 1.71, 1.55 \[1.01, 2.59\]Free triiodothyronine (pg/mL)1.97 ± 0.38, 2.04 \[1.75, 2.29\]Free thyroxine (ng/dL)1.00 ± 0.19, 1.01 \[0.90, 1.09\]Intact parathyroid hormone (pg/mL)155 ± 138, 110 \[70, 203\]Beta 2 microglobulin (mg/L)28.4 ± 9.1, 26.6 \[23.1, 31.2\]

Figure [1](#Fig1){ref-type="fig"} shows the relationship between BSFS and SBMs at the baseline. BSFS and SBMs were significantly related (Kendall rank correlation coefficient tau = 0.650, *p* \< 0.001). Bayesian statistics confirmed the significance of the result. Fig. 1BSFS and SBMs in baseline. Kendall rank correlation coefficient was 0.650 (*P* \< 0.001). SBMs, spontaneous bowel movements; BSFS, Bristol Stool Form Scale

The internal consistency test result (Cronbach's alpha) of 0.956 and the reliability coefficient of 0.899, obtained by Guttman's split-half method, confirmed the PAC-QOL questionnaire's reliability. Table [3](#Tab3){ref-type="table"} shows the PAC-QOL scores, SBMs, and BSFS score at baseline and after 4 weeks of elobixibat 10 mg/day intake. There were significant decreases in the scores for physical discomfort from 1.94 ± 0.79 to 0.97 ± 0.72 (*p* \< 0.001); psychosocial discomfort from 1.16 ± 0.93 to 0.63 ± 0.58 (*p* \< 0.001); worries/ concerns from 1.84 ± 0.73 to 1.27 ± 0.59 (*p* \< 0.001); and satisfaction scores from 2.79 ± 0.61 to 1.98 ± 0.77 (*p* \< 0.001). The total PAC-QOL score significantly decreased from 1.83 ± 0.67 to 1.17 ± 0.56 (*p* \< 0.001). The number of SBMs per week increased significantly from 2.6 ± 1.2 to 4.1 ± 2.1 (*p* \< 0.001). BSFS scores at baseline were "1" for 13 persons, "2" for 10 persons, "3" for 2 persons, and "4" for 2 persons. BSFS scores at 4 weeks changed to "2" for 3 persons, "3" for 5 persons, "4" for 18 persons, and "5" for 1 person. The BSFS score significantly improved from 1.9 ± 0.8 to 3.6 ± 0.7 (*p* \< 0.001). Bayesian statistics confirmed the results' significance. Table 3PAC-QOL, SBM, and Bayes factor at baseline and week 4Baseline\
Mean ± SD, median \[IQR\]Week 4\
Mean ± SD, median \[IQR\]*P* valueBayes factorPAC-QOL Global score1.83 ± 0.671.17 ± 0.56\< 0.001\< 0.0011.93 \[1.29, 2.36\]1.14 \[0.71, 1.57\] Physical discomfort1.94 ± 0.790.97 ± 0.72\< 0.001\< 0.0012.00 \[1.25, 2.50\]1.00 \[0.50, 1.50\] Psychosocial discomfort1.16 ± 0.930.63 ± 0.58\< 0.0010.0100.88 \[0.25, 2.00\]0.50 \[0.00, 1.00\] Worries and concerns1.84 ± 0.731.27 ± 0.59\< 0.0010.0012.00 \[1.09, 2.45\]1.18 \[0.82, 1.91\] Satisfaction2.79 ± 0.611.98 ± 0.77\< 0.0010.0022.80 \[2.40, 3.40\]2.00 \[1.60, 2.60\] Weekly SBM2.6 ± 1.24.1 ± 2.1\< 0.001\< 0.0012 \[2, 3\]4 \[2, 5\] Bristol Stool Form Scale score1.9 ± 0.83.6 ± 0.7\< 0.0010.0072 \[1, 2\]4 \[3, 4\]*PAC-QOL* Patients Assessment of Constipation-Quality of Life, *SBM* spontaneous bowel movement

Figure [2](#Fig2){ref-type="fig"} shows the relationship between changes in BSFS and SBMs in 4-week elobixibat intake. BSFS and SBMs were significantly related (Kendall rank correlation coefficient tau = 0.468, *p* = 0.004). Bayesian statistics moderately supported the significance of the result. Fig. 2Changes in BSFS and changes in SBMs after 4-week elobixibat intake. Kendall rank correlation coefficient was 0.650 (*P* \< 0.001). SBMs, spontaneous bowel movements; BSFS, Bristol Stool Form Scale

We divided the patients into two groups according to the number of laxatives.

Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"} show the PAC-QOL scores, SBMs, and BSFS scores at baseline and after 4 weeks in the two groups. Table 4PAC-QOL, SBM, and Bayes factor at baseline and at week 4 in patients taking 1 laxative (*N* = 13)Baseline\
Mean ± SD, median \[IQR\]Week 4\
Mean ± SD, median \[IQR\]*P* valueBayes factorPAC-QOL Global score1.68 ± 0.631.13 ± 0.420.0020.0071.64 \[1.14, 2.31\]1.00 \[0.77, 1.34\] Physical discomfort1.79 ± 0.660.92 ± 0.530.0040.0261.75 \[1.00, 2.38\]0.75 \[0.50, 1.13\] Psychosocial discomfort0.94 ± 0.880.48 ± 0.470.0170.2850.75 \[0.19, 1.57\]0.25 \[0.07, 0.88\] Worries and concerns1.73 ± 0.741.24 ± 0.520.0230.2192.00 \[1.05, 2.32\]1.09 \[0.82, 1.64\] Satisfaction2.66 ± 0.542.09 ± 0.540.0090.0852.40 \[2.30, 3.10\]1.80 \[1.60, 2.50\] Weekly SBM2.6 ± 1.24.1 ± 2.10.0050.0712 \[2, 3\]4 \[2, 5\] Bristol Stool Form Scale score1.9 ± 0.93.6 ± 0.60.0040.0102 \[1, 3\]4 \[3, 4\] Table 5PAC-QOL, SBM, and Bayes factor at baseline and week 4 in patients taking 2 or 3 laxatives (*N* = 14)Baseline\
Mean ± SD, median \[IQR\]Week 4\
Mean ± SD, median \[IQR\]*P* valueBayes factorPAC-QOL Global score1.97 ± 0.681.21 ± 0.670.0020.0092.00 \[1.44, 2.52\]1.41 \[0.43, 1.69\] Physical discomfort2.07 ± 0.880.76 ± 0.640.0020.0202.00 \[1.25, 2.75\]0.82 \[0.00, 1.50\] Psychosocial discomfort1.36 ± 0.930.63 ± 0.580.0120.1741.57 \[0.56, 2.13\]0.50 \[0.00, 1.00\] Worries and concerns1.95 ± 0.711.30 ± 0.650.0020.0102.09 \[1.29, 2.57\]1.45 \[0.64, 1.96\] Satisfaction2.90 ± 0.641.87 ± 0.930.0040.0563.00 \[2.35, 3.45\]2.00 \[1.10, 2.65\] Weekly SBM2.3 ± 1.03.2 ± 1.50.0270.3632 \[2, 3\]3 \[2, 4\] Bristol Stool Form Scale score1.8 ± 0.83.6 ± 0.80.0020.0012 \[1, 2\]4 \[3, 4\]

As shown in Table [4](#Tab4){ref-type="table"}, scores decreased for physical discomfort from 1.79 ± 0.66 to 0.92 ± 0.53 (*p* = 0.004); psychosocial discomfort from 0.94 ± 0.88 to 0.48 ± 0.47 (*p* = 0.017); worries/ concerns from 1.73 ± 0.74 to 1.24 ± 0.52 (*p* = 0.023); and satisfaction from 2.66 ± 0.54 to 2.09 ± 0.54 (*p* = 0.009). The total PAC-QOL score significantly decreased from 1.68 ± 0.63 to 1.13 ± 0.42 (*p* = 0.002), whereas the number of SBMs per week increased from 2.6 ± 1.2 to 4.1 ± 2.1 (*p* = 0.005). The BSFS score significantly improved from 1.9 ± 0.0 to 3.6 ± 0.6 (*p* = 0.004). Bayesian statistics confirmed the significance of these results.

As shown in Table [5](#Tab5){ref-type="table"}, scores decreased for physical discomfort from 2.07 ± 0.88 to 0.76 ± 0.64 (*p* = 0.002); psychosocial discomfort from 1.36 ± 0.93 to 0.63 ± 0.58 (*p* = 0.012); worries/ concerns from 1.95 ± 0.71 to 1.30 ± 0.65 (*p* = 0.002); and satisfaction from 2.90 ± 0.64 to 1.87 ± 0.93 (*p* = 0.004). The total PAC-QOL score significantly decreased from 1.97 ± 0.68 to 1.21 ± 0.67 (*p* = 0.002), whereas the number of SBMs per week increased from 2.3 ± 1.0 to 3.2 ± 1.5 (*p* = 0.027). The BSFS score significantly improved from 1.8 ± 0.8 to 3.6 ± 0.8 (*p* = 0.002). Bayesian statistics confirmed the significance of these results.

Table [6](#Tab6){ref-type="table"} shows the levels of electrolytes and cholesterol at baseline and after 4 weeks of elobixibat 10 mg/day intake. Sodium, potassium, total calcium, phosphate, LDL, and HDL did not change significantly after elobixibat intake. Bayesian statistics confirmed the results. Table 6Electrolytes and cholesterol levels at baseline and week 4Baseline\
Mean ± SD, median \[IQR\]Week 4\
Mean ± SD, median \[IQR\]*P* valueBayes factorSodium (mEq/L)139 ± 3139 \[136, 141\]139 ± 3139 \[137, 141\]0.3934.112Potassium (mEq/L)4.6 ± 0.8, 4.6 \[4.2, 5.1\]4.7 ± 0.8 4.7 \[4.0, 5.0\]0.9096.485Total calcium (mg/dL)8.5 ± 0.6, 8.5 \[8.1, 8.7\]8.4 ± 0.7 8.5 \[7.9, 8.8\]0.2875.125Phosphate (mg/dL)4.9 ± 1.2, 4.5 \[4.0, 5.8\]5.2 ± 1.3, 5.2 \[4.1, 6.1\]0.1193.973LDL (mg/dL)80 ± 28, 79 \[54, 106\]78 ± 25, 75 \[55, 107\]0.1034.692HDL (mg/dL)41 ± 14, 41 \[31, 50\]43 ± 14, 41 \[33, 47\]0.3063.968*LDL* low-density lipoprotein cholesterol, *HDL* high-density lipoprotein cholesterol

Discussion {#Sec7}
==========

The present study revealed that supplemental administration of elobixibat to hemodialysis patients with chronic constipation improved their PAC-QOL, SBMs, and BSFS, without significantly affecting the levels of sodium, potassium, total calcium, phosphate, LDL, and HDL. Hard stools were significantly related to SBMs, and softening stools were significantly related to increase in SBMs.

Defecation is a necessary physiological function, and its failure poses a major problem in daily life. The prevalence of chronic constipation had been about 16% in the general population \[[@CR17]\] and was reported to be higher, at about 36 to 66%, in hemodialysis patients \[[@CR2]\]. However, the reliability on self-reporting is debatable when diagnosing constipation because patient's perception may not accurately indicate the actual problem.

Constipation that does not improve and unpredictable defecation can cause gradual anxiety and dissatisfaction, thereby restricting daily life activities. Indeed, chronic constipation can greatly impair a patient's QOL, and addressing it was shown to improve both physical and mental QOL \[[@CR1]\]. We evaluated the QOL of chronic constipation using PAC-QOL. PAC-QOL is the most widely used disease-specific quality of life measure for chronic constipation. In a recent study, PAC-QOL was also used to evaluate various clinical presentations of functional constipation, irritable bowel syndrome with constipation, and No Rome Constipation in Italy \[[@CR18]\].

Treatment for chronic constipation usually begins with diet and lifestyle improvement as well as appropriate exercise. If these changes do not help, medications or surgery may be recommended \[[@CR19]\]. Chronic constipation may also be associated with colonic or rectal anatomo-functional alternations as colonic inertia or rectal outlet obstruction, respectively. The re-educative treatment and rehabilitation of the harmony of the "imaginary cuboid" constituted by the diaphragm, abdominal wall, spine and pelvic floor may be important \[[@CR20]--[@CR22]\].

Elobixbat is a pure enantiomer of synthetically modified 1,5-benzothiazepine with a seven-membered heterocyclic ring attached to a benzene ring (chemical formula C~36~H~45~N~3~O~7~S~2~) \[[@CR23], [@CR24]\]. The main route of elimination of elobixibat is in the feces. There is little excretion in the urine. The estimated half-life in humans is less than 4 h. The binding rate to human plasma proteins in vitro is more than 99%, and the human blood cell migration rate is less than 5%. After oral ingestion of ^14^C-elobixibat, there was no accumulation of elobixibat or associated metabolites within the plasma or urine \[[@CR23]\]. Multiple clinical trials evaluating the use of elobixibat have demonstrated consistent improvements in stool frequency and consistency and clinically meaningful end points across various populations diagnosed with chronic idiopathic constipation \[[@CR5], [@CR6], [@CR25]--[@CR27]\]. However, no studies have evaluated the use of this drug in dialysis patients with chronic constipation. In the current study, we demonstrated for the first time that adding elobixibat to drugs for constipation improved hemodialysis patients' QOL.

Hemodialysis patients usually undergo dialysis three times per week. If a patient feels the urge to defecate during dialysis, the dialysis needs to be temporarily stopped. If patients cannot make it to a toilet in time, they may inadvertently excrete in the presence of medical staff and other patients in the room, which can cause great mental distress for patients. Therefore, defecation on four non-dialysis days a week, and avoiding defecation on dialysis days three times per week may be desirable. In the current study, elobixibat was shown to increase the number of SBMs from 2.6 to 4.1 times per week. Hemodialysis patients are generally considered to pass hard stools because of the restrictions in the intake of dietary fiber and water, as well as water removal by dialysis. Aging-associated muscle atrophy affects both skeletal and smooth muscles, including those in the digestive tract, thereby affecting digestive tract motor function \[[@CR28]\]. In elderly dialysis patients, hard stools make defecation more difficult. Elobixibat softens the stool by inhibiting the reabsorption of bile acids. In this study, elobixibat significantly improved the BSFS score and changes in BSFS were related to changes in SBMs. This implied that the softened stools made defecation easier and increased weekly defecation frequency, which may have led to the improvement in the PAC-QOL.

Elobixibat was reported to lower serum LDL cholesterol by approximately 10% \[[@CR29]\]. However, in this study, the LDL and HDL levels did not change significantly after elobixibat administration for 4 weeks. Although lubiprostone was reported to decrease serum IP levels in hemodialysis patients \[[@CR30]\], electrolytes did not change significantly in this study.

The present study had several limitations. First, this study was conducted using questionnaires, and we could not exclude the potential effects of other unknown confounders. Second, it was retrospective observational study. Nevertheless, this was, to the best of our knowledge, the first multicenter observational study that evaluated the efficacy of elobixibat in hemodialysis patients with chronic constipation. Furthermore, this study's reliability was confirmed by Bayesian inference. However, further investigation on a larger sample size from multiple centers is necessary for external validity. Finally, the generalizability of our results on the efficacy of elobixibat in hemodialysis patients needs to be verified in a large-scale, randomized controlled study with other drugs or without elobixibat.

Conclusion {#Sec8}
==========

In conclusion, additional intake of elobixibat improved the PAC-QOL score, BSFS score, and SBM frequency in hemodialysis patients with chronic constipation, especially those with hard stools and poor stool rhythm. Further investigation is necessary to ascertain our findings.
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